More Checks And Balances For Orphan Drugs Needed, Says Germany’s G-BA
Executive Summary
The German pricing and reimbursement authority wants better scrutiny of orphan drug designations and incentives for orphan drug development to help address the access problem.
You may also be interested in...
Interview: Eucope On Turning Ten, Defending Orphan Incentives And Securing Market Access For Cell And Gene Therapies
Ten years on from its inception, the European Confederation of Pharmaceutical Entrepreneurs is focused on defending the incentives system for developing orphan drugs.
EU Orphan Designations Fall Sharply In 2017
The number of medicines awarded orphan designation in the EU has fallen for the first time since 2013. In 2017 there were 144, considerably fewer than in 2016 when there were 209. In the meantime, orphan drug advocacy group Eurordis says radical change is needed if patients are to have broader access to these important but often highly priced drugs.
Lessons From Europe: Orphan Drug Valuations Show Limits Of Cost Effectiveness
Biogen, Sanofi executives says US should learn from experience of European health technology assessment bodies as Institute for Clinical and Economic Review embarks on initiative to adapt its value framework to orphan drugs.